RSV immunization in adults and children: A practical guide for clinicians.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39231605.
- Also identified by DOI 10.3949/ccjm.91.s1.03.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In 2023 and 2024, 3 vaccines were approved by the US Food and Drug Administration (FDA) against respiratory syncytial virus (RSV) in adults. In addition, the first long-acting RSV monoclonal antibody for infants and young children was approved. This review provides clinicians with practical guidance to navigate this new era of RSV prevention.
Medical subject headings
- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Virus Vaccines